PRESS RELEASES Auransa Announcements Featured August 7, 2024 First patient in Asia receives AU409 following the ongoing first-in-human clinical trial in the US for liver cancer August 7, 2024 August 7, 2024 September 27, 2023 Seven AI/ML for Life Sciences Companies Identified as Innovators in New Seven AI/ML for Life Sciences Companies Identified as Innovators in New Clarivate Companies to Watch Report September 27, 2023 September 27, 2023 September 14, 2023 AI-Biopharma Auransa Announces Successful First Patient Dosed in Phase 1 Clinical Trial for Liver Cancer September 14, 2023 September 14, 2023 March 23, 2023 USC Norris collaborates with Auransa on clinical trial of new targeted treatment for liver cancer and other solid tumors March 23, 2023 March 23, 2023 November 3, 2022 FDA Acceptance of Auransa's IND Application for AU409 for Treatment of Patients with Hepatocellular Carcinoma November 3, 2022 November 3, 2022 August 9, 2022 POLARISqb and Auransa Announce Promising Results for Triple Negative Breast Cancer using Quantum Computing and AI August 9, 2022 August 9, 2022 June 4, 2021 Auransa and POLARISqb enter research collaboration finding treatments for neglected women's diseases June 4, 2021 June 4, 2021 September 23, 2019 AU-409: a Novel, AI-Derived Drug Candidate for the Treatment of Hepatocellular Carcinoma September 23, 2019 September 23, 2019 December 19, 2018 Auransa Enters into Exclusive Licensing Agreement with China Oncology Focus Limited, an Affiliate of Lee’s Pharmaceutical Holdings, for Rights to AU018 in Greater China and Southeast Asia December 19, 2018 December 19, 2018 Interested in working together? CONTACT US
